23andMe to delist from Nasdaq, deregister with SEC
Regeneron Pharmaceuticals said earlier this month that it will acquire "substantially all" of 23andMe's assets for $256 million.
You are not logged in so some information on this page has been withheld. To see more, please log in.
Pharmaceuticals
since
auto-detected in 92 stories
6 days ago
14 days ago
Regeneron Pharmaceuticals to buy 23andMe and its data for $256 million
Regeneron is acquiring "substantially all" of 23andMe's assets for $256 million following a bankruptcy auction.
41 days ago
How Takeda's CEO transformed the company into a global pharma powerhouse
Takeda Pharmaceuticals, Japan's largest drugmaker, has undergone a sweeping transformation under CEO Christophe Weber, emerging as one of the world's leading pharmaceutical companies.
How Takeda's CEO transformed the company into a global pharma powerhouse
found
a story from CNBC ⚠ › World News
Takeda Pharmaceuticals, Japan's largest drugmaker, has undergone a sweeping transformation under CEO Christophe Weber, emerging as one of the world's leading pharmaceutical companies.
page 1 of 1